Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)
Other Adverse Events Observed During Postmarketing Evaluation of REMERON section:
- Increased creatine kinase blood levels and rhabdomyolysis have also been reported
- Starting Remeron in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome
- There may be circumstances when it is necessary to initiate treatment with an MAOI such as linezolid or intravenous methylene blue in a patient taking Remeron. Remeron should be discontinued before initiating treatment with the MAOI.
Who should not take Remeron?
- Ask your healthcare provider or pharmacist if you are not sure if you take an MAOI, including the antibiotic linezolid.